Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .
Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
OBJECTIVES To examine the effect of alpha 1D/A adrenoceptor inhibitor naftopidil on health-related quality of life ( QOL ) in men with benign prostatic hyperplasia ( BPH ) . METHODS A total of 56 newly diagnosed patients with symptomatic BPH were prospect ively enrolled and treated with 50 mg naftopidil daily for more than 12 weeks . All underwent pre-treatment documentation of lower urinary tract symptoms , QOL assessment using the international prostate symptom score ( IPSS ) and King 's Health Question naire ( KHQ ) , and uroflowmetry . A post-treatment assessment was performed at 12 weeks . RESULTS IPSS scores as well as QOL index showed a significant improvement after naftopidil administration . Similarly , all seven domains except general health perceptions and social limitations in the KHQ question naire were significantly improved . When dividing the patients into overactive bladder ( OAB ) and non-OAB groups , only the OAB group showed significant improvement in almost all the domains of KHQ . Change ratios of the IPSS were not associated with those of KHQ domain scores in the OAB group . On the other h and , in the non-OAB group more domains presented improvements , which were associated with those of IPSS scores . CONCLUSIONS Twelve-week treatment with naftopidil for symptomatic BPH patients is associated with significant improvement in the IPSS , QOL index , maximum urinary flow rate , post-void residual urine volume ( PVR ) and almost all domains in KHQ . KHQ is useful for the evaluation of clinical response in BPH patients , particularly in those with associated OAB
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .